{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:22:51Z","timestamp":1788009771275,"version":"build-2784847793"},"reference-count":28,"publisher":"BMJ","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.m1315","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T14:36:15Z","timestamp":1588084575000},"page":"m1315","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":117,"title":["Pregabalin and gabapentin for pain"],"prefix":"10.1136","author":[{"given":"Stephanie","family":"Mathieson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wei Christine","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Eldabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"2020051907263121000_369.apr28_2.m1315.1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2020051907263121000_369.apr28_2.m1315.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2020051907263121000_369.apr28_2.m1315.3","unstructured":"National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings. National Institute for Health and Care Excellence. 2017. http:\/\/guidance.nice.org.uk\/CG173"},{"key":"2020051907263121000_369.apr28_2.m1315.4","unstructured":"Compendium EM . https:\/\/www.medicines.or.uk\/emc\/"},{"key":"2020051907263121000_369.apr28_2.m1315.5","unstructured":"Therapeutic Goods Administration. LYRICA pregabalin 300mg capsule bottle. 2019. https:\/\/www.ebs.tga.gov.au\/servlet\/xmlmillr6?dbid=ebs\/PublicHTML\/pdfStore.nsf&docid=3E21B96419C675E0CA2583D900424C4A&agid=(PrintDetailsPublic)&actionid=1."},{"key":"2020051907263121000_369.apr28_2.m1315.6","unstructured":"Therapeutic Goods Administration. GABAPENTIN-GA gabapentin 400 mg capsule blister pack. 2010. https:\/\/www.ebs.tga.gov.au\/servlet\/xmlmillr6?dbid=ebs\/PublicHTML\/pdfStore.nsf&docid=7B8F66B0802EE9F3CA2577DD00032FC8&agid=(PrintDetailsPublic)&actionid=1."},{"key":"2020051907263121000_369.apr28_2.m1315.7","unstructured":"Pfizer Inc. Lyrica prescribing information. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021446s026,022488s005lbl.pdf"},{"key":"2020051907263121000_369.apr28_2.m1315.8","unstructured":"Pfizer Inc. Neurotin prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020235s064_882s047_1129s046lbl.pdf"},{"key":"2020051907263121000_369.apr28_2.m1315.9","doi-asserted-by":"crossref","first-page":"E786","DOI":"10.1503\/cmaj.171333","article-title":"Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis","volume":"190","author":"Enke","year":"2018","journal-title":"CMAJ"},{"key":"2020051907263121000_369.apr28_2.m1315.10","doi-asserted-by":"crossref","unstructured":"Linde M Mulleners WM Chronicle EP McCrory DC . Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010609.","DOI":"10.1002\/14651858.CD010609"},{"key":"2020051907263121000_369.apr28_2.m1315.11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrd.2018.42","article-title":"Market watch: top drugs and companies by sales in 2017","volume":"17","author":"Urquhart","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2020051907263121000_369.apr28_2.m1315.12","unstructured":"OpenPrescribing.net. EBM DataLab, University of Oxford, 2019. https:\/\/openprescribing.net."},{"key":"2020051907263121000_369.apr28_2.m1315.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4441"},{"key":"2020051907263121000_369.apr28_2.m1315.14","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S168504"},{"key":"2020051907263121000_369.apr28_2.m1315.15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manag Healthc Policy"},{"key":"2020051907263121000_369.apr28_2.m1315.16","doi-asserted-by":"crossref","unstructured":"Derry S Bell RF Straube S Wiffen PJ Aldington D Moore RA . Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019;1:CD007076.","DOI":"10.1002\/14651858.CD007076.pub3"},{"key":"2020051907263121000_369.apr28_2.m1315.17","doi-asserted-by":"crossref","unstructured":"Wiffen PJ Derry S Bell RF . Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;6:CD007938.","DOI":"10.1002\/14651858.CD007938.pub4"},{"key":"2020051907263121000_369.apr28_2.m1315.18","doi-asserted-by":"crossref","unstructured":"Derry S Cording M Wiffen PJ Law S Phillips T Moore RA . Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev 2016;9:CD011790.","DOI":"10.1002\/14651858.CD011790.pub2"},{"key":"2020051907263121000_369.apr28_2.m1315.19","doi-asserted-by":"crossref","unstructured":"Cooper TE Derry S Wiffen PJ Moore RA . Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev 2017;1:CD012188.","DOI":"10.1002\/14651858.CD012188.pub2"},{"key":"2020051907263121000_369.apr28_2.m1315.20"},{"key":"2020051907263121000_369.apr28_2.m1315.21","doi-asserted-by":"crossref","unstructured":"Gomes T Juurlink DN Antoniou T Mamdani MM Paterson JM van den Brink W . Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med 2017;14:e1002396.","DOI":"10.1371\/journal.pmed.1002396"},{"key":"2020051907263121000_369.apr28_2.m1315.22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0700-x"},{"key":"2020051907263121000_369.apr28_2.m1315.23","unstructured":"Department of Veterans\u2019 Affairs. Managing neuropathic pain: a stepwise approach. 2013. https:\/\/www.apsoc.org.au\/PDF\/Publications\/Veterans_MATES_35_Neuropathic_Pain_TherBrief_JUN13.pdf"},{"key":"2020051907263121000_369.apr28_2.m1315.24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res Manag"},{"key":"2020051907263121000_369.apr28_2.m1315.25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.24869\/psyd.2018.142","article-title":"On the addictive power of gabapentinoids: a mini-review","volume":"30","author":"Bonnet","year":"2018","journal-title":"Psychiatr Danub"},{"key":"2020051907263121000_369.apr28_2.m1315.26","unstructured":"Public Health England. NHS England. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. 2014. ttps:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/385791\/PHE-NHS_England_pregabalin_and_gabapentin_advice_Dec_2014.pdf"},{"key":"2020051907263121000_369.apr28_2.m1315.27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3111\/13696998.2011.632797","article-title":"A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain","volume":"15","author":"Gordon","year":"2012","journal-title":"J Med Econ"},{"key":"2020051907263121000_369.apr28_2.m1315.28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2217\/cer-2018-0008","article-title":"Cost of treating peripheral neuropathic pain with pregabalin or gabapentin at therapeutic doses in routine practice","volume":"7","author":"Sicras-Mainar","year":"2018","journal-title":"J Comp Eff Res"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.m1315","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.m1315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T03:58:52Z","timestamp":1601092732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.m1315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":28,"alternative-id":["10.1136\/bmj.m1315"],"URL":"https:\/\/doi.org\/10.1136\/bmj.m1315","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}